Precision Business Insights

Portfolio

Research Reports

SELECT LICENSE TYPE
Databank $ 2,000.00
spinner
Single User $ 3,000.00
spinner
Multiple User $ 4,000.00
spinner
Corporate User $ 6,000.00
spinner
buy now spinner

Why Precision Business Insights?

  • Pre and Post Sale Support

    Get in touch with our industry experts to resolve your research queries before and after buying the report. Avail free 60 minutes analyst tele-call to get additional market information before and after purchase

  • Special Pricing and Discounts

    Avail special pricing for the purchase of report sections,regional insights, and historical data. Discounts for government bodies, research institutes, universities, NGO’s and start-up’s

  • In-depth Market Analysis

    Our research reports provides holistic market information with 360 degree analysis. We adopt 3 pronged strategy to analyze the market i.e. Secondary research , primary research, and expert validation

  • Accurate and Reliable Market Data

    Utmost focus on delivering accurate and reliable research reports. We adopt internally developed data mining tools to eliminate any data errors

  • NICHE AND GROWTH MARKETS EXPERTISE

    Proven expertise in delivering new and emerging markets product and technology advancements. We provide market information across the developed and emerging markets

  • ADHERING TO QUICK DELIVERY TIME LINES

    We provide impeccable research reports in quick turnaround time

Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018


 

Available formats:    

StumbleUponEmail

Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment: Clinical Trails Analysis, Player Profiles, Collaborations, Key Targets, Geographic Focus, and Data Publications, 2018

 

Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment

 

Overview:

Amyotrophic lateral sclerosis is the most common degenerative disease of the motor neuron system, enables destroy nerve cells and causes disability. Amyotrophic lateral sclerosis is known as Lou Gehring’s disease.

Amyotrophic lateral sclerosis often begins with muscle twitching and weakness in a limb, or slurred speech. Afterwards, may affects the control of the muscles involved in movement, speaking, eating and breathing. There is no cure for the disease and eventually disease is fatal.

The disease is inherited in 5% to 10% of cases and rest is unknown etiology. Researchers are studying several possible causes including gene mutation, chemical imbalance, and protein mishandling and disorganized immune response.Amyotrophic lateral sclerosis is difficult to diagnose, because it mimics various neurological disease symptoms. Generally ALS diagnosed using electromyogram, nerve conduction study, MRI, spinal tap and muscle biopsy. Blood and urine test are performed to sort out the other possible signs and symptoms.

Two FDA approved drugs are available in the market, namely Riluzole and endaravone. Various therapies are available to reduce the symptoms of the disease.

 

Segmentation:

The pipeline drugs are segmented based on route of administration, trial phase,and company

By route of administration, amyotrophic lateral sclerosis pipeline drugs are segmented into

  • Oral
  • Parenteral
  • Others

By trial phase, amyotrophic lateral sclerosis pipeline drugs are segmented into

  • Pre-clinical phase
  • Phase-I
  • Phase II
  • Phase-III

By company, amyotrophic lateral sclerosis pipeline drugs are segmented into

  • Mallinckrodt Pharmaceuticals
  • ASTELLAS PHARMA INC. (JAPAN)
  • REVALESIO CORPORATION (U.S.)
  • Amylyx Pharmaceutical Corp. (U.S.)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • AB Science (France)
  • H. Boehringer Sohn AG &Co. KG (Germany)

 

Space Analysis:

Most of the pipeline drugs for treatment of amyotrophic lateral sclerosis pipeline are at preclinical stages. Companies with pipeline molecules mostly focused on neuroprotection, immunomodulation,andglutamate excitotoxicity blockers for the treatment of amyotrophic lateral sclerosis.

  • In November 2017, U.S. Food and Drug Administration has given clearance of the clinical investigation of Biohaven Pharmaceutical’s sublingual lead, BHV-0223 for the treatment of amyotrophic lateral sclerosis.
  • In September 2017, U.S. Food and Drug Administration granted orphan drug designation to Revalesio’s investigational drug RNS60 to treat Amyotrophic Lateral Sclerosis (ALS).

 

Report Description:

Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment report studies the various therapeutics under clinical development for uterine fibroids treatment along with targets for various drug candidate. The report provides plethora of information pertaining to trail phases, companies involved in the uterine fibroids pipeline drugsdevelopment. This report studies the dynamics of the Amyotrophic Lateral SclerosisPipeline Drugs i.e. drivers, challenges,andopportunities which are significantly impacting the product development. The report provides various information pertaining the clinical trials such as designation, grants, patents, and technology among others. Moreover, the report on uterine fibroids pipeline drugs assessment comprehensively presents the geographic location, trial status information along with key players involved in the therapeutics development.

 

Key Features of the Report:

  • Provides the information related to universities and research institutes working in the therapeutics development
  • Report comprehensively covers the all active and discontinued studies
  • Studies the entire pipeline with special emphasis on companies actively involved in the therapeutics development
  • Presents the prominent targets for drug development in each stage of clinical trial
  • Provides the in-depth analysis of each drug candidates in the clinical trial phases
  • Mallinckrodt Pharmaceuticals
  • ASTELLAS PHARMA INC. (JAPAN)
  • REVALESIO CORPORATION (U.S.)
  • Amylyx Pharmaceutical Corp. (U.S.)
  • Mitsubishi Tanabe Pharma Corporation (Japan)
  • AB Science (France)
  • H. Boehringer Sohn AG &Co. KG (Germany)

1. Executive Summary

 

2. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Introduction

 

2.1. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Taxonomy

2.2. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market –Definitions

2.2.1. Route of Administration

2.2.2. Trial Phase

 

3. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics

 

3.1. Drivers

3.2. Restraints

3.3. Opportunities/Unmet Needs of the Market

3.4. Trends

3.5. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamic Factors – Impact Analysis

3.6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Competition Landscape

3.7. Epidemiology

 

4. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis,2013 – 2017 and Forecast, 2018 – 2024

 

4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

4.2. Year-over-Year (Y-o-Y) Growth Analysis (%)

4.3. Market opportunity analysis

 

5. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market, By Route of Administration, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

5.1. Oral

5.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.1.3. Market Opportunity Analysis

5.2. Parenteral

5.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.2.3. Market Opportunity Analysis

5.3. Others

5.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

5.3.3. Market Opportunity Analysis

 

6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Forecast, By Trial Phase,2013 – 2017 and Forecast, 2017 – 2024

 

6.1. Pre-clinical phase

6.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.1.3. Market Opportunity Analysis

6.2. Phase-I

6.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.2.3. Market Opportunity Analysis

6.3. Phase II

6.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.3.3. Market Opportunity Analysis

6.4. Phase-III

6.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

6.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

6.4.3. Market Opportunity Analysis

 

7. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Forecast, By Region, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

7.1. North America

7.1.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.1.3. Market Opportunity Analysis

7.2. Europe

7.2.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.2.3. Market Opportunity Analysis

7.3. Asia-Pacific

7.3.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.3.3. Market Opportunity Analysis

7.4. Latin America

7.4.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.4.3. Market Opportunity Analysis

7.5. Middle East and Africa

7.5.1. Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)

7.5.3. Market Opportunity Analysis

7.6. Global Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase and Region, 2018 – 2024

 

8. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment MarketAnalysis,2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

8.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

8.1.1. Oral

8.1.2. Parenteral

8.1.3. Others

8.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

8.2.1. Pre-clinical phase

8.2.2. Phase-I

8.2.3. Phase II

8.2.4. Phase-III

8.3. Country Analysis 2016 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

8.3.1. U.S.

8.3.2. Canada

8.4. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country, 2018 – 2024

8.5. North America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics – Trends

 

9. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

9.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

9.1.1. Oral

9.1.2. Parenteral

9.1.3. Others

9.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

9.2.1. Pre-clinical phase

9.2.2. Phase-I

9.2.3. Phase II

9.2.4. Phase-III

9.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

9.3.1. Germany

9.3.2. UK

9.3.3. France

9.3.4. Spain

9.3.5. Italy

9.3.6. Russia

9.3.7. Poland

9.3.8. Rest of Europe

9.4. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 – 2024

9.5. Europe Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics – Trends

 

10. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

10.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

10.1.1. Oral

10.1.2. Parenteral

10.1.3. Others

10.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

10.2.1. Pre-clinical phase

10.2.2. Phase-I

10.2.3. Phase II

10.2.4. Phase-III

10.3. Country Analysis2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)       

10.3.1. Japan

10.3.2. China

10.3.3. India

10.3.4. ASEAN

10.3.5. Australia & New Zealand

10.3.6. Rest of Asia-Pacific

10.4. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 – 2024

10.5. Asia-Pacific Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics – Trends

 

11. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2012 – 2012 – 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

11.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

11.1.1. Oral

11.1.2. Parenteral

11.1.3. Others

11.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

11.2.1. Pre-clinical phase

11.2.2. Phase-I

11.2.3. Phase II

11.2.4. Phase-III

11.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

11.3.1. Brazil

11.3.2. Mexico

11.3.3. Argentina

11.3.4. Venezuela

11.3.5. Rest of Latin America

11.4. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 – 2024

11.5. Latin America Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics – Trends

 

12. Middle East and Africa Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Analysis, 2013 – 2017 and Forecast, 2018 – 2024 (Revenue, USD Mn)

 

12.1. Route of Administration Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn),Y-o-Y Growth (%), and Market Share (%)

12.1.1. Oral

12.1.2. Parenteral

12.1.3. Others

12.2. Trial Phase Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)

12.2.1. Pre-clinical phase

12.2.2. Phase-I

12.2.3. Phase II

12.2.4. Phase-III

12.3. Country Analysis 2013 – 2017 and Forecast 2018 – 2024 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)

12.3.1. Gulf Cooperation Council (GCC) Countries

12.3.2. Israel

12.3.3. South Africa

12.3.4. Rest of MEA

12.4. MEA Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market – Opportunity Analysis Index, By Route of Administration, By Trial Phase and Country,2018 – 2024

12.5. MEA Amyotrophic Lateral Sclerosis Pipeline Drugs Assessment Market Dynamics – Trends

 

13. Competition Landscape

 

13.1. Strategic Dashboard of Top Market Players

13.2. Company Profiles (Introduction, Financial Analysis, Route of Administration& Service Offerings, Key Developments, Strategies, and SWOT Analysis)

13.2.1. Mallinckrodt Pharmaceuticals

13.2.2. ASTELLAS PHARMA INC. (JAPAN)

13.2.3. REVALESIO CORPORATION (U.S.)

13.2.4. Amylyx Pharmaceutical Corp. (U.S.)

13.2.5. Mitsubishi Tanabe Pharma Corporation (Japan)

13.2.6. AB Science (France)

13.2.7. H. Boehringer Sohn AG &Co. KG (Germany)

 

14. Research Methodology

15. Key Assumptions and Acronyms

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Avail Discount  Up To 20%

Need more discount on this report?

Call or e-mail us for:

(U.S.) – +1-866-598-1553

Contact SalesTOLL FREE: +1-866-598-1553